GlassScriptPhysician profile
Rina Goldberg
NPI 1306954730
$7,333.87
in general payments reported to CMS, 2019-2025
44 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $107 · 2021: $531 · 2022: $786 · 2023: $823 · 2024: $3,575 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,513 · Travel and Lodging: $1,818 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,513.18 |
| Travel and Lodging | $1,817.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| H. Lundbeck A S | $1,817.84 | 2024 | |
| Supernus Pharmaceuticals, INC. | $748.78 | 2021-2025 | Qelbree, Qelbree |
| Ucb, INC. | $555.02 | 2020-2025 | Fintepla, Briviact, Nayzilam |
| Acadia Pharmaceuticals INC | $343.20 | 2023-2025 | Daybue |
| Sk Life Science, INC. | $324.32 | 2021-2025 | |
| Abbvie INC. | $319.30 | 2021-2025 | |
| Neurelis, INC. | $266.23 | 2021-2025 | Valtoco |
| Ironshore Pharmaceuticals INC. | $239.71 | 2019-2024 | Jornay Pm |
| Corium, LLC | $226.84 | 2022-2025 | Azstarys, Azstarys |
| Biocodex, INC. | $221.17 | 2023-2025 | Diacomit |
| Aucta Pharmaceuticals, INC. | $157.29 | 2024-2025 | Motpoly Xr |
| Tris Pharma INC | $147.20 | 2020-2023 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $145.12 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $131.25 | 2019-2024 | Austedo Xr |
| Lundbeck LLC | $121.50 | 2022-2025 | Vyepti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rina Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.